

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
ECKERT, et al.

Examiner: **HAMA, Joanne**

Art Unit: **1632**

Application No.: **10/088,139**

Filed: **December 17, 2002**

Conf. No. **1457**

Title: **TRANSGENEIC ANIMAL EXPRESSING A MULTIPLE MUTATED
FORM OF PRESENILIN I**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicant's duty of disclosure pursuant to 37 C.F.R. §1.56.

The submission of the document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any right to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

Under 37 C.F.R. §1.97(c), as the submission is filed after the period specified in §1.97(b) but before the mailing date of any of a final action under §1.113, a notice of allowance under §1.311, or an action that otherwise closes prosecution in the application. Applicants hereby authorize the Commissioner to charge any fees under 37 C.F.R. §1.17(p), or credit any overpayment, to Deposit Account No. **18-1982**.

Respectfully submitted,

/George S Jones/
George S. Jones, Reg. No. 38,508

Sanofi US
U.S. Patent Operations
1041 Route 202-206
Mail Code: BWD-303A
Bridgewater, New Jersey 08807
email: **uspatent.e-filing@sanofi-aventis.com**
Telephone: (908) 231-3776
Telefax: (908) 231-2626
Sanofi US Ref. ST99042 US PCT
Date: January 11, 2012